A new group of drugs called enzalutamide for people with advanced prostate cancer has shown a steady increase in survival rates of 67% following 5 years.
The treatment, developed by a research group under the supervision of Dr. Christopher Sweeney, Director of the Cancer Immunology Institute at the University of South Australia, depends on suppressing testosterone, with or without chemotherapy.
related topics
The study’s trials were published in The Lancet Oncology journal, and the survival rate following receiving the new treatment is 67%, while the rate with the standard treatment currently used is 57%.
“The long-term analysis showed that the benefit of adding enzalutamide was evident in all subgroups of patients, regardless of when the cancer had spread, how far it had spread, or whether people had also received docetaxel chemotherapy,” Dr. Sweeney said.
He added: “These high-level results indicate that the addition of enzalutamide should be considered as a treatment option for any patient who is able to receive it. And that it may not be necessary to add other treatments such as chemotherapy.
Responsibility for the news: Cedar News is not responsible for this news in form or content, and it only expresses the point of view of its source or writer.